Stonegate Capital Partners has updated its coverage on Burcon Nutrascience Corporation (TSX: BU), highlighting the company's transition from technology validation to commercial execution. Burcon's fiscal first-quarter results for 2027 show notable progress, with revenue increasing 54% sequentially and 273% year-over-year to $1.28 million. The number of active buying customers grew to 40 from over 30 previously, and repeat purchasing continues to build, providing better visibility into recurring demand.
However, the quarter also included a $1.76 million inventory write-down, which masked a much narrower underlying gross loss. The focus now shifts to whether the improving customer traction can support the sizable second-half revenue ramp required to reach the prior CY26 sales objective. Burcon is expanding its Galesburg capacity and moving toward positive cash flow, making capacity and funding key execution levers.
The company has planned an up-to-$8.1 million financing to bridge liquidity and support the production ramp. The second-half ramp remains substantial; the prior $10 million CY26 sales target would require approximately $7.9 million in second-half sales. Achieving positive cash flow remains an important milestone for the company.
For more details, the full announcement is available here. Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Its affiliate, Stonegate Capital Markets (member FINRA), provides a full spectrum of investment banking services for public and private companies.
